Alamar Biosciences, Inc. filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on November 4, 2026, covering the fiscal quarter ended September 30, 2026.
Key Highlights
- Shares outstanding: As of October 31, 2026, the company had 69,481,651 shares of common stock, $0.0001 par value per share, outstanding.
- Filing status: The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company under SEC rules.
- Losses since inception: According to the filing, the company has incurred losses since inception and expects to incur losses in the future.
- Key product dependency: The filing states that revenue growth is significantly dependent on new assays for the ARGO HT instrument and new versions of that instrument.
- Government funding risk: The filing discloses that the business is "significantly dependent on researchers who rely heavily on government funding, including NIH grants."
- Competitive market: The filing identifies the proteomics market as "highly competitive" and flags competitive failure as a risk to financial condition and results of operations.
Alamar Biosciences Reports Q3 2026 Financial Position and Key Risk Factors
Alamar Biosciences, Inc. (NASDAQ:ALMR), headquartered at 47071 Bayside Parkway, Fremont, California 94538, submitted its Form 10-Q for the quarterly period ended September 30, 2026. The filing covers the company's condensed consolidated financial statements, management discussion and analysis, and an extensive set of risk factor disclosures in Part II, Item 1A.
According to the filing, the company has incurred losses since inception and expects to continue incurring losses, noting that it "may not be able to generate sufficient revenue to achieve and maintain cash flows from operating activities in excess of our capital investment requirements or to achieve and sustain profitability." The filing also discloses that the company's limited operating history makes it difficult to evaluate future prospects and the risks and challenges it may encounter.
The filing highlights product-related risks, stating that if the company does not successfully develop and introduce new assays for its ARGO HT instrument and new versions of that instrument, it "may not generate new sources of revenue and may not be able to successfully implement our growth strategy." Additionally, the filing notes that a significant portion of revenue comes from research and development spending by research and academic institutions, which are themselves dependent on government funding such as NIH grants. Any reduction, modification, or delay in such funding, the filing states, "could adversely affect our sales and financial performance." The forward-looking statements contained in the filing are the company's own and are subject to its cautionary language as described in the Special Note Regarding Forward-Looking Statements.
What Was Disclosed
Alamar Biosciences filed its September 30, 2026 quarterly report disclosing 69,481,651 shares outstanding as of October 31, 2026, ongoing operating losses since inception, product development risks tied to its ARGO HT instrument, and significant dependence on government-funded research customers.




Please wait processing your request...